

Robert F Siliciano

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3240183/robert-f-siliciano-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

187 papers	27,811 citations	89 h-index	166 g-index
210 ext. papers	32,080 ext. citations	16.6 avg, IF	6.93 L-index

#	Paper	IF	Citations
187	Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. <i>Science</i> , 1997 , 278, 1295-300	33.3	2379
186	Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. <i>Nature Medicine</i> , 1999 , 5, 512-7	50.5	1681
185	Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. <i>Nature</i> , 1997 , 387, 183-8	50.4	1654
184	Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. <i>Nature Medicine</i> , 2003 , 9, 727-8	50.5	1187
183	Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. <i>Cell</i> , 2013 , 155, 540-51	56.2	898
182	In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. <i>Nature Medicine</i> , 1995 , 1, 1284-90	50.5	581
181	Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. <i>Immunity</i> , 2012 , 36, 491-501	32.3	570
180	The challenge of viral reservoirs in HIV-1 infection. <i>Annual Review of Medicine</i> , 2002 , 53, 557-93	17.4	500
179	Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. <i>Annual Review of Immunology</i> , 2000 , 18, 665-708	34.7	438
178	Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. <i>PLoS Pathogens</i> , 2013 , 9, e1003174	7.6	422
177	Defective proviruses rapidly accumulate during acute HIV-1 infection. <i>Nature Medicine</i> , 2016 , 22, 1043-9	50.5	413
176	A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. <i>Nature</i> , 1988 , 331, 78-81	50.4	410
175	Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. <i>Nature</i> , 2015 , 517, 381-5	50.4	377
174	New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. <i>Nature Medicine</i> , 2014 , 20, 425-9	50.5	364
173	Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion. <i>Cell</i> , 1988 , 54, 561-75	56.2	359
172	HIV latency. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011 , 1, a007096	5.4	354
171	Redefining the viral reservoirs that prevent HIV-1 eradication. <i>Immunity</i> , 2012 , 37, 377-88	32.3	324

170	Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. <i>Journal of Virology</i> , 2006 , 80, 6441-57	6.6	321
169	HIV-1 integration landscape during latent and active infection. <i>Cell</i> , 2015 , 160, 420-32	56.2	289
168	An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. <i>PLoS Pathogens</i> , 2013 , 9, e1003834	7.6	283
167	Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 817-29	27.4	281
166	Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1901-12	15.9	275
165	Control of HIV despite the discontinuation of antiretroviral therapy. <i>New England Journal of Medicine</i> , 1999 , 340, 1683-4	59.2	272
164	Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. <i>Nature</i> , 1985 , 317, 428-30	50.4	271
163	Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. <i>Journal of Virology</i> , 2004 , 78, 6122-33	6.6	267
162	Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. <i>Nature Medicine</i> , 2008 , 14, 762-6	50.5	249
161	The HBV drug entecavir - effects on HIV-1 replication and resistance. <i>New England Journal of Medicine</i> , 2007 , 356, 2614-21	59.2	231
160	Proliferation of latently infected CD4 T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. <i>Journal of Experimental Medicine</i> , 2017 , 214, 959-972	16.6	228
159	A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. <i>Nature</i> , 2019 , 566, 120-125	35.4	227
158	Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. <i>Journal of Virology</i> , 2007 , 81, 2508-18	6.6	227
157	Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. <i>Journal of Experimental Medicine</i> , 2006 , 203, 1357-69	16.6	221
156	Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. <i>Journal of Virology</i> , 2002 , 76, 8518-31	6.6	202
155	The multifactorial nature of HIV-1 latency. <i>Trends in Molecular Medicine</i> , 2004 , 10, 525-31	11.5	198
154	Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. <i>PLoS Pathogens</i> , 2013 , 9, e1003347	7.6	196
153	Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 13475-80	11.5	195

152	Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. <i>Journal of Clinical Investigation</i> , 2009 , 119, 3473-86	15.9	186
151	Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. <i>PLoS Pathogens</i> , 2013 , 9, e1003398	7.6	183
150	Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. <i>Methods in Molecular Biology</i> , 2005 , 304, 3-15	1.4	180
149	Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. <i>Cell Host and Microbe</i> , 2017 , 21, 494-506.e4	23.4	176
148	HIV reservoirs: what, where and how to target them. <i>Nature Reviews Microbiology</i> , 2016 , 14, 55-60	22.2	176
147	Viral dynamics in HIV-1 infection. <i>Cell</i> , 1998 , 93, 665-71	56.2	176
146	BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. <i>Cell Cycle</i> , 2013 , 12, 452-62	4.7	169
145	Experimental approaches to the study of HIV-1 latency. <i>Nature Reviews Microbiology</i> , 2007 , 5, 95-106	22.2	169
144	Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. <i>Cell Host and Microbe</i> , 2008 , 4, 134-46	23.4	166
143	Targeting the Latent Reservoir for HIV-1. <i>Immunity</i> , 2018 , 48, 872-895	32.3	166
142	Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. <i>Journal of Infectious Diseases</i> , 2004 , 189, 1452-65	6.7	164
141	Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. <i>Journal of Virology</i> , 2005 , 79, 2199-210	6.6	163
140	Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. <i>PLoS Pathogens</i> , 2006 , 2, e68	7.6	162
139	Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. <i>Journal of Experimental Medicine</i> , 1997 , 185, 909-20	16.6	158
138	Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. <i>Journal of Virology</i> , 2004 , 78, 1718-29	6.6	157
137	Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. <i>Journal of Virology</i> , 2002 , 76, 4138-44	6.6	156
136	Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. <i>Journal of Virology</i> , 2011 , 85, 6060-4	6.6	155
135	Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. <i>Journal of Allergy and Clinical Immunology</i> , 2008 , 122, 22-8	11.5	154

134	Towards an HIV-1 cure: measuring the latent reservoir. <i>Trends in Microbiology</i> , 2015 , 23, 192-203	12.4	152
133	Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. <i>Journal of Infectious Diseases</i> , 2007 , 195, 833-6	7	149
132	Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. <i>Journal of Virology</i> , 2003 , 77, 7383-92	6.6	143
131	Latency in human immunodeficiency virus type 1 infection: no easy answers. <i>Journal of Virology</i> , 2003 , 77, 1659-65	6.6	143
130	Screening for noise in gene expression identifies drug synergies. <i>Science</i> , 2014 , 344, 1392-6	33.3	142
129	A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2014 , 58, 883-90	11.6	142
128	G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. <i>Journal of Virology</i> , 2005 , 79, 1975-80	6.6	142
127	Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. <i>Journal of Virology</i> , 2006 , 80, 4758-70	6.6	136
126	Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. <i>Journal of Virology</i> , 2008 , 82, 1870-83	6.6	135
125	Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E2575-E2584	11.5	131
124	Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. <i>Journal of Virology</i> , 2000 , 74, 7824-33	6.6	129
123	Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. <i>Nature Medicine</i> , 2012 , 18, 1378-85	50.5	128
122	The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site. <i>Journal of Virology</i> , 2001 , 75, 181-91	6.6	128
121	A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. <i>Journal of Clinical Investigation</i> , 2000 , 105, 995-1003	15.9	124
120	Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. <i>Cell</i> , 2012 , 148, 1271-83	56.2	123
119	A quantitative basis for antiretroviral therapy for HIV-1 infection. <i>Nature Medicine</i> , 2012 , 18, 446-51	50.5	122
118	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. <i>PLoS Medicine</i> , 2017 , 14, e1002417	11.6	122
117	A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. <i>Journal of Virology</i> , 2009 , 83, 9247-57	6.6	120

116	Targeting HIV latency: pharmacologic strategies toward eradication. <i>Drug Discovery Today</i> , 2013 , 18, 541-51	8.8	115
115	The mTOR Complex Controls HIV Latency. <i>Cell Host and Microbe</i> , 2016 , 20, 785-797	23.4	115
114	Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. <i>Journal of Virology</i> , 2004 , 78, 9105-14	6.6	114
113	Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. <i>Journal of Virology</i> , 2002 , 76, 9481-92	6.6	110
112	Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. <i>Journal of Virology</i> , 2009 , 83, 8470-81	6.6	108
111	Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. <i>Journal of Virology</i> , 2008 , 82, 8307-15	6.6	107
110	Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 4832-7	11.5	105
109	Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. <i>Journal of Clinical Investigation</i> , 2013 , 123, 3848-60	15.9	105
108	Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2018 , 128, 876-889	15.9	104
107	Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. <i>Journal of Virology</i> , 2010 , 84, 7018-28	6.6	100
106	Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. <i>Journal of Virology</i> , 2003 , 77, 4938-49	6.6	100
105	Distinct viral reservoirs in individuals with spontaneous control of HIV-1. <i>Nature</i> , 2020 , 585, 261-267	50.4	97
104	Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. <i>Clinical Infectious Diseases</i> , 2006 , 42, 1189-96	11.6	96
103	The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence. <i>Journal of Immunology</i> , 2016 , 197, 407-17	5.3	96
102	Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. <i>Journal of Virology</i> , 2011 , 85, 5384-93	6.6	95
101	A long-term latent reservoir for HIV-1: discovery and clinical implications. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 54, 6-9	5.1	93
100	Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4 T Cells Permissive for Latent HIV-1 Infection. <i>Immunity</i> , 2017 , 47, 766-775.e3	32.3	92
99	Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv123	1	91

98	Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. <i>Aids</i> , 2017 , 31, 5-14	3.5	87
97	Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. <i>Journal of Virology</i> , 2004 , 78, 968-79	6.6	86
96	Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T cells. <i>Nature</i> , 1993 , 364, 158-61	50.4	86
95	HIV latency and integration site placement in five cell-based models. <i>Retrovirology</i> , 2013 , 10, 90	3.6	85
94	HIV-1 viral load blips are of limited clinical significance. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 803-5	5.1	83
93	Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. <i>Journal of Virology</i> , 2008 , 82, 7395-410	6.6	82
92	HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2012 , 205, 1014-8	7	79
91	Developing strategies for HIV-1 eradication. <i>Trends in Immunology</i> , 2012 , 33, 554-62	14.4	77
90	CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells. <i>PLoS ONE</i> , 2014 , 9, e110731	3.7	72
89	Nuclear landscape of HIV-1 infection and integration. <i>Nature Reviews Microbiology</i> , 2017 , 15, 69-82	22.2	71
88	Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. <i>PLoS Pathogens</i> , 2016 , 12, e1005535	7.6	67
87	A novel PCR assay for quantification of HIV-1 RNA. <i>Journal of Virology</i> , 2013 , 87, 6521-5	6.6	64
86	Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 134, 12-9	11.5	63
85	Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. <i>Journal of Virology</i> , 2009 , 83, 5028-34	6.6	63
84	From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. <i>BioEssays</i> , 2013 , 35, 544-52	4.1	62
83	Progress Toward HIV Eradication: Case Reports, Current Efforts, and the Challenges Associated with Cure. <i>Annual Review of Medicine</i> , 2016 , 67, 215-28	17.4	61
82	Measuring the Frequency of Latent HIV-1 in Resting CD4+ T Cells Using a Limiting Dilution Coculture Assay. <i>Methods in Molecular Biology</i> , 2016 , 1354, 239-53	1.4	61
81	No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2010 , 201, 293-6	7	59

80	Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. <i>PLoS Pathogens</i> , 2007 , 3, e122	7.6	57
79	Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1030-7	11.6	56
78	HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. <i>Journal of Clinical Investigation</i> , 2018 , 128, 3102-3115	15.9	56
77	A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. <i>Science Translational Medicine</i> , 2011 , 3, 91ra63	17.5	54
76	Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. <i>JCI Insight</i> , 2020 , 5,	9.9	53
75	HIV-1 eradication strategies: design and assessment. <i>Current Opinion in HIV and AIDS</i> , 2013 , 8, 318-25	4.2	52
74	Re-evaluating evolution in the HIV reservoir. <i>Nature</i> , 2017 , 551, E6-E9	50.4	51
73	Recent developments in the effort to cure HIV infection: going beyond N = 1. <i>Journal of Clinical Investigation</i> , 2016 , 126, 409-14	15.9	51
72	A mechanistic theory to explain the efficacy of antiretroviral therapy. <i>Nature Reviews Microbiology</i> , 2014 , 12, 772-80	22.2	50
71	Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs. <i>Nature Communications</i> , 2012 , 3, 716	17.4	50
70	The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. <i>Aids</i> , 2008 , 22, 541-4	3.5	47
69	Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. <i>Journal of Clinical Investigation</i> , 2017 , 127, 651-656	15.9	45
68	Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. <i>Current Opinion in Immunology</i> , 2004 , 16, 470-6	7.8	44
67	Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. <i>Retrovirology</i> , 2011 , 8, 97	3.6	43
66	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. <i>Nature Medicine</i> , 2020 , 26, 1339-1350	50.5	43
65	Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict Clonality. <i>PLoS Pathogens</i> , 2016 , 12, e1005689	7.6	42
64	Different human resting memory CD4 T cell subsets show similar low inducibility of latent HIV-1 proviruses. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	38
63	Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir. <i>Retrovirology</i> , 2018 , 15, 21	3.6	38

62	The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections. <i>Cell Host and Microbe</i> , 2019 , 26, 73-85.e4	23.4	38
61	Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 6321-6	11.5	38
60	Recent trends in HIV-1 drug resistance. <i>Current Opinion in Virology</i> , 2013 , 3, 487-94	7.5	36
59	HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. <i>Journal of Virology</i> , 2014 , 88, 3340-52	6.6	36
58	Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 398-403	5.1	36
57	HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. <i>Journal of Virology</i> , 2016 , 90, 4511-4519	6.6	35
56	A primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. <i>Nature Protocols</i> , 2014 , 9, 2755-70	18.8	35
55	Insight into treatment of HIV infection from viral dynamics models. <i>Immunological Reviews</i> , 2018 , 285, 9-25	11.3	33
54	Evolution of the HIV-1 nef gene in HLA-B*57 positive elite suppressors. <i>Retrovirology</i> , 2010 , 7, 94	3.6	33
53	CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans. <i>Science Advances</i> , 2018 , 4, eaat0843	14.3	30
52	Diverse fates of uracilated HIV-1 DNA during infection of myeloid lineage cells. <i>ELife</i> , 2016 , 5,	8.9	30
51	The role of CD32 during HIV-1 infection. <i>Nature</i> , 2018 , 561, E17-E19	50.4	30
50	Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivo. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	29
49	Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3543-3559	15.9	28
48	The latent reservoir for HIV-1 in resting CD4+ T cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials. <i>Current Opinion in HIV and AIDS</i> , 2006 , 1, 62-8	4.2	26
47	The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure. <i>Current Opinion in HIV and AIDS</i> , 2006 , 1, 121-8	4.2	25
46	Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 18692-18700	11.5	24
45	Reservoir expansion by T-cell proliferation may be another barrier to curing HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1692-4	11.5	23

44	Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. <i>Antiviral Therapy</i> , 2009 , 14, 263-271	1.6	23
43	Finding a cure for human immunodeficiency virus-1 infection. <i>Infectious Disease Clinics of North America</i> , 2014 , 28, 633-50	6.5	21
42	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance. <i>ACS Medicinal Chemistry Letters</i> , 2015 , 6, 1075-9	4.3	19
41	Incentives for Viral Suppression in People Living with HIV: A Randomized Clinical Trial. <i>AIDS and Behavior</i> , 2019 , 23, 2337-2346	4.3	19
40	HIV: Early treatment may not be early enough. <i>Nature</i> , 2014 , 512, 35-6	50.4	19
39	Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 759-61	1.6	19
38	Assays to Measure Latency, Reservoirs, and Reactivation. <i>Current Topics in Microbiology and Immunology</i> , 2018 , 417, 23-41	3.3	18
37	Endothelial cell stimulation overcomes restriction and promotes productive and latent HIV-1 infection of resting CD4+ T cells. <i>Journal of Virology</i> , 2013 , 87, 9768-79	6.6	18
36	Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2005 , 13, 96-100		18
35	Treatment implications of the latent reservoir for HIV-1. <i>Advances in Pharmacology</i> , 2007 , 55, 411-25	5.7	15
34	HIV persistence: clonal expansion of cells in the latent reservoir. <i>Journal of Clinical Investigation</i> , 2017 , 127, 2536-2538	15.9	15
33	Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions. <i>PLoS Pathogens</i> , 2016 , 12, e1005679	7.6	15
32	HIV: Not-so-innocent bystanders. <i>Nature</i> , 2014 , 505, 492-3	50.4	14
31	Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1308-1315	11.6	14
30	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	14
29	What do we need to do to cure HIV infection. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2010 , 18, 104-8		14
28	AIDS/HIV. Rekindled HIV infection. <i>Science</i> , 2014 , 345, 1005-6	33.3	12
27	Quantitative evaluation of the antiretroviral efficacy of dolutegravir. <i>JCI Insight</i> , 2016 , 1, e90033	9.9	12

26	Biomarkers of HIV replication. <i>Current Opinion in HIV and AIDS</i> , 2010 , 5, 491-7	4.2	11
25	Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4 T Cells. <i>Journal of Virology</i> , 2020 , 95,	6.6	11
24	Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 32066-32077	11.5	11
23	Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1973-e1981	11.6	11
22	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. <i>Journal of Virology</i> , 2021 , 95,	6.6	11
21	HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 15763-15771	11.5	10
20	Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 1434-42	1.6	9
19	Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure. <i>Journal of Infectious Diseases</i> , 2021 , 223, 13-21	7	8
18	Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 6860-1	11.5	7
17	Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responses. <i>PLoS ONE</i> , 2018 , 13, e0192098	3.7	7
16	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. <i>Nature Communications</i> , 2021 , 12, 1474	17.4	7
15	Reservoirs for HIV-1. <i>Current Infectious Disease Reports</i> , 1999 , 1, 298-304	3.9	6
14	Nonsuppressible HIV-1 viremia: a reflection of how the reservoir persists. <i>Journal of Clinical Investigation</i> , 2020 , 130, 5665-5667	15.9	6
13	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. <i>Lancet HIV</i> , 2020 , 7, e602-e610	7.8	6
12	Similar Frequency and Inducibility of Intact Human Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. <i>Journal of Infectious Diseases</i> , 2021 , 224, 258-268	7	5
11	Stoichiometric parameters of HIV-1 entry. <i>Virology</i> , 2015 , 474, 1-9	3.6	4
10	Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. <i>Journal of Infectious Diseases</i> , 2021 , 223, 1905-1913	7	4
9	A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. <i>Annals of Internal Medicine</i> , 2021 ,	8	3

8	Multiple genetic programs contribute to CD4 T cell memory differentiation and longevity by maintaining T cell quiescence. <i>Cellular Immunology</i> , 2020 , 357, 104210	4.4	3
7	Making sense of HIV innate sensing. <i>Immunity</i> , 2013 , 39, 998-1000	32.3	2
6	HIV Prevention and Treatment Fields Join Forces. <i>EBioMedicine</i> , 2014 , 1, 4-5	8.8	2
5	Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103 and Gut CD4 T Cells. <i>Journal of Virology</i> , 2020 , 95,	6.6	2
4	Measurement of antiviral activity in drugs for HIV-1. <i>Lancet Infectious Diseases, The</i> , 2011 , 11, 888-9	25.5	1
3	TCR-mimic bispecific antibodies to target the HIV-1 reservoir.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2123406119	11.5	0
2	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.. <i>Npj Vaccines</i> , 2022 , 7, 53	9.5	0
1	Reply: To PMID 25117799. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 136, 214	11.5	